Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s MHLW Designates Three Drugs As Orphan Drugs

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labour and Welfare designated three drugs as orphan drugs, including two items for one drug for different indications. They are: Otsuka's tuberculoses drug OPC-67683 for preventing multi-drug resistance, currently in Phase II trials overseas; Celgene's CC-5013 (lenalidomide) for treating multiple myeloma in Phase I trials in Japan; and Celgene's CC-5013 for treating anemia caused by myelodysplastic syndrome. MHLW also reported that Chugai's Herceptin 60 and 150 injection is expected to be approved in March. (Click for more-Japanese language

You may also be interested in...

Busy Week For Japanese Firm Otsuka: Justice Dept. Settlement For Off-Label Abilify Marketing And New Partnership With MethylGene

Abilify developer Otsuka Pharmaceutical settled with the U.S. Department of Justice over charges the company illegally marketed the atypical antipsychotic off-label for pediatric and elderly populations in the U.S. from 2002 through 2005

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts